Gadopiclenol

Gadopiclenol
Names
Trade namesElucirem
IUPAC name
  • 2-[3,9-bis[1-carboxylato-4-(2,3-dihydroxypropylamino)-4-oxobutyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]-5-(2,3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+)
Clinical data
Drug classGadolinium complex[1]
Main usesMRI contrast agent used to detect abnormal blood vessels[1]
Side effectsPain at the site of injection, headache, nausea, dizziness[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		Intravenous
Typical dose0.1 mL/kg[1]
Legal
License data
Legal status
Pharmacokinetics
MetabolismNone[1]
ExcretionKidneys[1]
Chemical and physical data
FormulaC35H54GdN7O15
Molar mass970.10 g·mol−1
3D model (JSmol)
SMILES
  • [Gd+3].OCC(O)CNC(=O)CCC(N1CCN(Cc2cccc(CN(CC1)C(CCC(=O)NCC(O)CO)C(=O)[O-])n2)C(CCC(=O)NCC(O)CO)C(=O)[O-])C(=O)[O-]
InChI
  • InChI=1S/C35H57N7O15.Gd/c43-19-24(46)14-36-30(49)7-4-27(33(52)53)40-10-12-41(28(34(54)55)5-8-31(50)37-15-25(47)20-44)17-22-2-1-3-23(39-22)18-42(13-11-40)29(35(56)57)6-9-32(51)38-16-26(48)21-45;/h1-3,24-29,43-48H,4-21H2,(H,36,49)(H,37,50)(H,38,51)(H,52,53)(H,54,55)(H,56,57);/q;+3/p-3
  • Key:GNRQMLROZPOLDG-UHFFFAOYSA-K

Gadopiclenol, sold under the brand name Elucirem, is a contrast agent used in magnetic resonance imaging (MRI) to detect lesions with abnormal blood vessels.[1] It may be used in those who are at least two years old.[1] It is given by injection into a vein.[1]

Common side effects include pain at the site of injection, headache, nausea, and dizziness.[1] Other side effects may include nephrogenic systemic fibrosis, allergic reactions, and retention of gadolinium.[1] Safety in pregnancy is unclear.[1] It is a paramagnetic macrocyclic non-ionic complex of gadolinium.[1]

Gadopiclenol was approved for medical use in the United States in 2022.[1] As of 2022 it is being looked at the approval agency in Europe.[3]

Medical use

Dosage

It is generally given at a dose of 0.1 mL/kg.[1]

Names

Gadopiclenol is the international nonproprietary name (INN).[4]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
  2. ↑ "Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
  3. ↑ "FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging". Pharmacy Times. Archived from the original on 27 September 2022. Retrieved 16 December 2022.
  4. ↑ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
External sites:
Identifiers:
  • Clinical trial number NCT03996447 for "Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PICTURE)" at ClinicalTrials.gov
  • Clinical trial number NCT03986138 for "Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.